Could you talk about the cost of buying nucleotides from TriLink and building the cap yourself versus the cost of having the end product cap as what you purchase; if not in dollar terms, maybe proportionate terms, like the end cap costs X percent more than buying the nucleotides and building it yourself, or is it just not that simple to think in those terms?

It's not that simple because you have to navigate the IP space, and the ability to do that chemical synthesis and purification is a very high upfront investment, to have those capabilities established in-house. You can have a vessel with enzymatic reaction, but if you start going into the chemistry of that, that in itself has a whole layer of build out and upfront costs associated with those. Unless you're big pharma that has the capabilities, that's not something you can in-source, so to speak. Even then, you still have to navigate the IP space, so you can't simply build the same structure.